The surge in market value is underpinned by a widespread shift toward automated laboratory workflows and stringent regulatory requirements for contamination control. Industrial testing currently leads the landscape, capturing a 56.8% share in 2025. This dominance is fueled by pharmaceutical and food manufacturing sectors that prioritize rapid release timelines and high-precision sterility assurance. Reagents and kits remain the primary product category, accounting for over half of the market as they become essential components in routine microbial identification and PCR-based workflows.

Clinical diagnostics also represent a critical growth pillar. Hospitals and clinical laboratories continue to adopt advanced molecular diagnostic platforms and antimicrobial susceptibility testing to combat the rising burden of healthcare-associated infections. North America remains the leading region for these technologies, benefiting from an established infrastructure of major biopharmaceutical entities and large-scale research institutions. Industry players such as Danaher Corporation, Thermo Fisher Scientific, and Bruker Corporation are increasingly integrating artificial intelligence and cloud-based informatics to enhance the sensitivity and speed of microbial detection systems.